منابع مشابه
Juvenile localized scleroderma: review of 44 patients
Results 70.5% of patients were females. CM (34.1%) and LM (34.1%) were the most frequently subtypes. Mean age at first symptoms was 7.7 years (Figure 1). Medium time between first signs/symptoms and diagnosis was 15.42 months. One patient with CM head-neck lesions had Parry-Romberg disease with neurological involvement. 50% of patients with head-neck LM had “coup de sabre” subtype, 25% of that ...
متن کاملEfficacy and safety of methotrexate treatment of juvenile localized scleroderma
Retrospective study of 59 chlidren with JLS from 3 to 17 y (M = 10.3) treated with MTX was performed. Group 1 (n = 18) – received prednisone 0.5 mg\kg for 6 weeks, taped to 0.1 mg\kg for 12 months + MTX 10 mg\body sq. weekly for 13.7 mo. Group 2 (n = 41) -MTX the same doses and duration. The efficacy was measured in 6 & 12 months using skin score, activity and sclerosis indexes (IA, IS) (1 – 3 ...
متن کاملLocalized scleroderma in a cohort of juvenile idiopathic arthritis children
Introduction Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Localized scleroderma also known as morphea is an inflammatory, fibrosing skin disorder that leads to sclerosis of the dermis and eventually of the underlying tissues. The prevalence is estimated at around 1-9/100,000 with the onset before 10 years of age in 2% of patients. The associatio...
متن کاملJuvenile localized scleroderma: Is it a benign disease?
Introduction: Juvenile localized scleroderma is a polymorphic disease. It is more prevalent in girls and has a significant morbidity. Extra-cutaneous involvement is common, and polyautoimmunity can reach 7%. The clinical characteristics of this disease in Colombian patients are currently unknown. Objective: To describe the clinical characteristics, morbidity and outcomes in patients with juveni...
متن کاملLong-term methotrexate efficacy in juvenile localized scleroderma
Methods We prospectively followed a cohort of patients with JLS who were enrolled in a double-blind, randomized controlled trial. Oral MTX was used at a dose of 15 mg/m once a week (max 20 mg) for at lest 24 months; prednisone (1 mg/Kg/day, max 50 mg), in a single morning dose for 3 months was added. A target lesion was evaluated clinically, with infrared thermography and using a computerized s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sri Lanka Journal of Child Health
سال: 2019
ISSN: 2386-110X,1391-5452
DOI: 10.4038/sljch.v48i4.8839